Zoetis Inc. $ZTS Shares Sold by BLB&B Advisors LLC

BLB&B Advisors LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 28.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,790 shares of the company’s stock after selling 21,917 shares during the period. BLB&B Advisors LLC’s holdings in Zoetis were worth $7,019,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Halbert Hargrove Global Advisors LLC raised its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in Zoetis during the 4th quarter valued at approximately $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis in the third quarter worth $31,000. Finally, Holos Integrated Wealth LLC acquired a new stake in Zoetis in the fourth quarter worth $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Trading Up 0.9%

Shares of ZTS stock opened at $121.11 on Wednesday. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The firm has a market capitalization of $50.94 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 1.83 and a beta of 0.98. The stock has a fifty day moving average of $122.10 and a two-hundred day moving average of $126.74. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company earned $1.40 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.